Repare Therapeutics Files Proxy Materials

TL;DR

Repare Therapeutics filed proxy docs, likely for a shareholder vote on something important.

AI Summary

Repare Therapeutics Inc. filed a Definitive Additional Materials (DEFA14A) on November 20, 2025, related to a "Support and Vot" agreement. The filing indicates no fee was required for this submission, which is a proxy statement.

Why It Matters

This filing provides shareholders with information regarding voting matters and potentially significant corporate actions, impacting their investment decisions.

Risk Assessment

Risk Level: low — This is a routine SEC filing for a proxy statement, not indicating immediate financial risk.

Key Players & Entities

• Repare Therapeutics Inc. (company) — Registrant
• 20251120 (date) — Filing Date
• DEFA14A (document_type) — Filing Type

FAQ

Filing Documents

• d849215ddefa14a.htm (DEFA14A) — 18KB
• g849215g1120094326852.jpg (GRAPHIC) — 4KB
• 0001193125-25-290058.txt ( ) — 24KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Repare Therapeutics Inc. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box): No feerequired. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11 Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc. CAMBRIDGE, Mass. & MONTREAL (BUSINESS WIRE) – November 20, 2025 – Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, "Xeno"), a non-profit biotechnology company, pursuant to which Xeno will acquire (the "Transaction") all of the issued and outstanding common shares of Repare (the "Common Shares"), certain entities affiliated with Biotechnology Value Fund, L.P., Blue Owl Capital Holdings LP, and certain entities affiliated with OrbiMed have each entered into a support and voting agreement pursuant to which they have agreed to vote their Common Shares in favor of the special resolution approving the Transaction. Considering the previously announced support and voting agreements entered into by the directors and executive officers of Repare, shareholders owning approximately 40% of Repare's issued and outstanding Common Shares have now agreed to vote their Common Shares in favor of the special resolution approving the Transaction. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics has developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-3467, a Phase 1 Pol ATPase inhibitor; and RP-1664, a Phase 1 PLK4 inhibitor. For more information, please visit www.reparerx.com and follow @Reparerx on X (formerly Twitter) and LinkedIn. Additional Information and Where to Find It The Company intends to file with the SEC and furnish to its shareholders a proxy statement on Schedule 14A, as well as other relevant documents concerning the proposed transaction. The proxy statement will contain important information about the proposed transaction and related matters. Investors and security holders of the Company are urged to carefully read the entire proxy statement (including any amendments or supplements thereto) when it becomes available because it will contain important information about the proposed transactions. A definitive proxy statement will be sent to the shareholders of the Company seeking any required shareholder approvals. Investors and security holders of the Company will be able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about the Company and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the SEC's website ( http://www.sec.gov ) or from the Company by contacting the Company's Investor Relations at (857) 412-7018, by submitting a contact form on the Company's website at https://www.reparerx.com/contact/, or by going to the Company's Investor Relations page on its website at https://ir.reparerx.com/investor-relations and clicking on the link titled "SEC Filings." Participants in the Solicitation The Company and certain of its directors, executive officers and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. Information regarding the interests of the Company's directors and executive officers and their ownership of the Company's common shares is set forth in the Company's annual report on Form 10-K filed with the SEC on March 3, 2025 and the Company's proxy statement on Schedule 14A filed with the SEC on April 29, 2025. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests in the proposed transaction, b

View Full Filing

View this DEFA14A filing on SEC EDGAR